CompletedPhase 2

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

United States75 participantsStarted 2004-04

Plain-language summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus * All histologic grades and stages eligible * Diagnosis by endometrial curettage or biopsy within the past 8 weeks * Must have the initial tissue block or 16 unstained sections of 5 micron thickness available * Performance status - GOG 0-3 * No history of thrombophlebitis or thromboembolic disorders * No other invasive malignancy within the past 5 years except nonmelanoma skin cancer * No prior therapeutic progesterone or anti-estrogen therapy within 3 months before diagnosis * No concurrent aminoglutethimide * No prior cancer treatment that would preclude study therapy * No concurrent bosentan * No concurrent rifampin

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative

Timeframe: During the hysterectomy, which is 21-24 days after administration of depo-provera

Trial details

NCT IDNCT00064025

SponsorGynecologic Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2010-09

Results submitted2014-01-31

View on ClinicalTrials.gov More Endometrial Adenocarcinoma trials